Microbial metabolite restores liver health by targeting PPARα and lipid metabolism through the gut-liver axis
Chronic liver diseases, including liver steatosis and fibrosis, are driven in part by dysregulation of PPARα and lipid metabolism. These diseases also generate gut barrier disruption and microbiome...
Read the full articleYou might also wanna read
Metabolic dysfunction–associated steatohepatitis exacerbated by Clostridium perfringens–derived ammonia is attenuated by tripeptide DT-109
The global prevalence of metabolic dysfunction–associated steatohepatitis (MASH) is rising, driven by a complex interplay of metabolic distu
Ammonia in the crosshairs: microbial targets for metabolic dysfunction–associated steatohepatitis prevention
Metabolic dysfunction–associated steatohepatitis (MASH) is increasingly linked to disruptions of the gut/liver axis, yet the microbial mecha
Hepatic SNHG9 links gut microbiota to liver protection in drug-induced liver injury
Unlock liver protection: Hepatic SNHG9, influenced by gut microbiota, is key against acetaminophen injury. Discover bridging pathways in dru
Inulin-Rich Prebiotic Vegetables May Help in Fatty Liver Disease Reversal
Fatty liver disease now affects almost 40% of the global population, 1 yet many don't even know they have it. It develops quietly through ye
Experimental drug reverses severe fatty liver disease by repairing the gut
An experimental drug called DT-109 reversed severe fatty liver disease in animal studies by repairing the gut and preventing harmful toxins
Experimental drug reverses severe fatty liver disease by repairing the gut
An experimental drug called DT-109 reversed severe fatty liver disease in animal studies by repairing the gut and preventing harmful toxins
Comments
Sign in to join the conversation.
No comments yet. Be the first.